An economic evaluation of the use of granulocyte colony-stimulating factor after bone marrow transplantation in children

PharmacoEconomics

Volumn 11, Issue 2, 1997, Pages 169-174

  Duncan, Nicholas ^a   Hewetson, Margaret ^a   Atra, Ayad ^a   Dick, Gina ^a   Pinkerton, Ross ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BONE MARROW TRANSPLANTATION; CANCER; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE COST; HUMAN; LEUKEMIA; LYMPHOMA; MALE; NEUTROPENIA; PHARMACOECONOMICS; PRIORITY JOURNAL;

EID: 0031028345     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199711020-00006     Document Type: Article

References (18)

1. Rowe JM, Ciobanu N, Ascensao J, et al. Recommended guidelines for the management of autologous and allogenic bone marrow transplantation. Ann Intern Med 1994; 120: 143-58
2. DeVita Jr VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th ed. Philadelphia: JB Lippincott Company, 1993: 283-6
3. Santos GW: Bone marrow transplantation in haematologic malignancies. Cancer 1990; 65: 786-91
4. Fabian I, Kletter Y, Bleiberg I, et al. Effect of exogenous recombinant human granulocyte and granulocyte-macrophage colony stimulating factor on neutrophil function following allogenic bone marrow transplantation. Exp Hematol 1991; 19: 868-73
5. Sheriden WP, Wolf M, Lusk J, et al. Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989; II: 891-5
6. Taylor KM, Jagannath S, Spitzer G, et al. Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's Disease. J Clin Oncol 1989; 7: 1791-9
7. Baker J. The impact of granulocyte colony stimulating factor (G-CSF) on the bone marrow transplantation programme (BMT) at the Queen Elizabeth Hospital [abstract no. P30]. International Symposium on Oncology Pharmacy Practice: 1993 Apr 22-24; Toronto, 33
8. Fairclough SJ. Cost benefit study of rG-CSF in paediatric autologous bone marrow transplantation patients [abstract no. P6]. International Symposium on Oncology Pharmacy Practice: 1993 Apr 22-24; Toronto, 27
9. Stahel RA, Muller E, Pichert G, et al. Dose intensification with autologous marrow support in high risk lymphoma: acceleration of hematopoietic recovery and reduction of days of hospitalisation with granulocyte colony stimulating factor (G-CSF) in a randomised open label trial [abstract]. Proc Am Soc Clin Oncol 1992; 11: 1129A
10. Blaise D, Vernant JP, Fiere D, et al. A randomised, controlled, multicenter trial of recombinant human granulocyte colony stimulating factor (filgrastim) in patients treated by bone marrow transplantation (BMT) with total body irradiation (TBI) for acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LL) [abstract]. Blood 1992; 80 Suppl. 1: 982A
11. Schmitz N, Dreger P, Zander A, et al. Recombinant human granulocyte colony stimulating factor (filgrastim) after autologous bone marrow transplantation for lymphoma: an open label randomised trial in Germany [abstract]. Blood 1992; 80 Suppl. 1: 1158A
12. Linch DC, Scarffe H, Proctor S, et al. Randomised vehicle-controlled dose-finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant 1993; 11: 307-11
13. Gisselbrecht C, Prentice HG, Bacigalupo A, et al. Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation. Lancet 1994; 343: 696-700
14. Faulds D, Lewis NJ, Milne RJ. Recombinant granulocyte colony-stimulating factor (rG-CSF). Pharmacoeconomics 1992; 1: 231-49
15. Brice P, Godin S, Libert O, et al. Effect of lenograstim on the cost of autologous bone marrow transplantation. Pharmacoeconomics 1995; 7: 238-41
16. British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. Number 28. London: British Medical Association and Royal Pharmaceutical Sociely of Great Britain, Sept 1994
17. Lieschke GJ, Ramenghi U, O'Connor MP, et al. Studies of oral neutrophil levels in patients receiving G-CSF after autologous marrow transplantation. Br J Haematol 1992; 82: 589-95
18. Gabrilove JL, Jakubowski J, Scher H, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional cell carcinoma of the urothelium. N Engl J Med 1988; 318: 1414-22